Heterogeneity of triple-negative breast cancer: Histologic subtyping to inform the outcome

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Background: This study assesses outcome in terms of disease-free survival (DFS) and overall survival (OS) of special types of triple-negative breast cancer (TNBC). Patients and Methods: We identified 8801 women with first primary nonmetastatic breast cancer operated on at the European Institute of Oncology between 1997 and 2005. Of these patients, 781 consecutive patients with immunohistochemically defined TNBC were selected for the analyses. We explored patterns of recurrence by histologic type. Median follow-up was 5.7 years (range 0-13 years). Results: The 5-year DFS was 77% for TNBC, 68% for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and 84% and 95% for luminal B and luminal A breast cancer, respectively. From 781 TNBC subtypes, 693 cases (89%) were classified as ductal not otherwise specified (NOS) (invasive ductal carcinoma [IDC]), 29 were classified as apocrine (3.7%), 18 (2.3%) were classified as lobular, 10 (1.2%) were classified as adenoid cystic, and 10 (1.2%) were classified as metaplastic. Five-year DFS and OS were 77% and 84% for patients with ductal carcinoma, 56% and 89% for patients with metaplastic carcinoma, and both 5-year DFS and OS were 100% for patients with adenoid cystic and medullary carcinomas, respectively. Conclusion: Distinct prognostic implications may derive from the specific histotype of TNBC. The identification of these special types has a significant clinical utility and should be considered in therapeutic algorithms.

Original languageEnglish
Pages (from-to)31-39
Number of pages9
JournalClinical Breast Cancer
Volume13
Issue number1
DOIs
Publication statusPublished - 2013

Fingerprint

Triple Negative Breast Neoplasms
Disease-Free Survival
Ductal Carcinoma
Breast Neoplasms
Survival
Adenoids
Adenoid Cystic Carcinoma
Medullary Carcinoma
Outcome Assessment (Health Care)
Carcinoma
Recurrence

Keywords

  • Adjuvant therapy
  • Breast cancer
  • Histologic subtype
  • Special types
  • Triple negative

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{7ed0a9ddf28f46e3b27ee3323151472c,
title = "Heterogeneity of triple-negative breast cancer: Histologic subtyping to inform the outcome",
abstract = "Background: This study assesses outcome in terms of disease-free survival (DFS) and overall survival (OS) of special types of triple-negative breast cancer (TNBC). Patients and Methods: We identified 8801 women with first primary nonmetastatic breast cancer operated on at the European Institute of Oncology between 1997 and 2005. Of these patients, 781 consecutive patients with immunohistochemically defined TNBC were selected for the analyses. We explored patterns of recurrence by histologic type. Median follow-up was 5.7 years (range 0-13 years). Results: The 5-year DFS was 77{\%} for TNBC, 68{\%} for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and 84{\%} and 95{\%} for luminal B and luminal A breast cancer, respectively. From 781 TNBC subtypes, 693 cases (89{\%}) were classified as ductal not otherwise specified (NOS) (invasive ductal carcinoma [IDC]), 29 were classified as apocrine (3.7{\%}), 18 (2.3{\%}) were classified as lobular, 10 (1.2{\%}) were classified as adenoid cystic, and 10 (1.2{\%}) were classified as metaplastic. Five-year DFS and OS were 77{\%} and 84{\%} for patients with ductal carcinoma, 56{\%} and 89{\%} for patients with metaplastic carcinoma, and both 5-year DFS and OS were 100{\%} for patients with adenoid cystic and medullary carcinomas, respectively. Conclusion: Distinct prognostic implications may derive from the specific histotype of TNBC. The identification of these special types has a significant clinical utility and should be considered in therapeutic algorithms.",
keywords = "Adjuvant therapy, Breast cancer, Histologic subtype, Special types, Triple negative",
author = "Emilia Montagna and Patrick Maisonneuve and Nicole Rotmensz and Giuseppe Cancello and Monica Iorfida and Alessandra Balduzzi and Viviana Galimberti and Paolo Veronesi and Alberto Luini and Giancarlo Pruneri and Luca Bottiglieri and Mastropasqua, {Mauro G.} and Aron Goldhirsch and Giuseppe Viale and Marco Colleoni",
year = "2013",
doi = "10.1016/j.clbc.2012.09.002",
language = "English",
volume = "13",
pages = "31--39",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Heterogeneity of triple-negative breast cancer

T2 - Histologic subtyping to inform the outcome

AU - Montagna, Emilia

AU - Maisonneuve, Patrick

AU - Rotmensz, Nicole

AU - Cancello, Giuseppe

AU - Iorfida, Monica

AU - Balduzzi, Alessandra

AU - Galimberti, Viviana

AU - Veronesi, Paolo

AU - Luini, Alberto

AU - Pruneri, Giancarlo

AU - Bottiglieri, Luca

AU - Mastropasqua, Mauro G.

AU - Goldhirsch, Aron

AU - Viale, Giuseppe

AU - Colleoni, Marco

PY - 2013

Y1 - 2013

N2 - Background: This study assesses outcome in terms of disease-free survival (DFS) and overall survival (OS) of special types of triple-negative breast cancer (TNBC). Patients and Methods: We identified 8801 women with first primary nonmetastatic breast cancer operated on at the European Institute of Oncology between 1997 and 2005. Of these patients, 781 consecutive patients with immunohistochemically defined TNBC were selected for the analyses. We explored patterns of recurrence by histologic type. Median follow-up was 5.7 years (range 0-13 years). Results: The 5-year DFS was 77% for TNBC, 68% for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and 84% and 95% for luminal B and luminal A breast cancer, respectively. From 781 TNBC subtypes, 693 cases (89%) were classified as ductal not otherwise specified (NOS) (invasive ductal carcinoma [IDC]), 29 were classified as apocrine (3.7%), 18 (2.3%) were classified as lobular, 10 (1.2%) were classified as adenoid cystic, and 10 (1.2%) were classified as metaplastic. Five-year DFS and OS were 77% and 84% for patients with ductal carcinoma, 56% and 89% for patients with metaplastic carcinoma, and both 5-year DFS and OS were 100% for patients with adenoid cystic and medullary carcinomas, respectively. Conclusion: Distinct prognostic implications may derive from the specific histotype of TNBC. The identification of these special types has a significant clinical utility and should be considered in therapeutic algorithms.

AB - Background: This study assesses outcome in terms of disease-free survival (DFS) and overall survival (OS) of special types of triple-negative breast cancer (TNBC). Patients and Methods: We identified 8801 women with first primary nonmetastatic breast cancer operated on at the European Institute of Oncology between 1997 and 2005. Of these patients, 781 consecutive patients with immunohistochemically defined TNBC were selected for the analyses. We explored patterns of recurrence by histologic type. Median follow-up was 5.7 years (range 0-13 years). Results: The 5-year DFS was 77% for TNBC, 68% for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and 84% and 95% for luminal B and luminal A breast cancer, respectively. From 781 TNBC subtypes, 693 cases (89%) were classified as ductal not otherwise specified (NOS) (invasive ductal carcinoma [IDC]), 29 were classified as apocrine (3.7%), 18 (2.3%) were classified as lobular, 10 (1.2%) were classified as adenoid cystic, and 10 (1.2%) were classified as metaplastic. Five-year DFS and OS were 77% and 84% for patients with ductal carcinoma, 56% and 89% for patients with metaplastic carcinoma, and both 5-year DFS and OS were 100% for patients with adenoid cystic and medullary carcinomas, respectively. Conclusion: Distinct prognostic implications may derive from the specific histotype of TNBC. The identification of these special types has a significant clinical utility and should be considered in therapeutic algorithms.

KW - Adjuvant therapy

KW - Breast cancer

KW - Histologic subtype

KW - Special types

KW - Triple negative

UR - http://www.scopus.com/inward/record.url?scp=84872336069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872336069&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2012.09.002

DO - 10.1016/j.clbc.2012.09.002

M3 - Article

C2 - 23098574

AN - SCOPUS:84872336069

VL - 13

SP - 31

EP - 39

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 1

ER -